Samsung Biologics and TG Therapeutics expand blood cancer partnership 27-Apr-2021 By Jane Byrne US biopharma firm, TG Therapeutics, has announced an expanded contract manufacturing deal with Samsung Biologics to support the production of its investigational anti-CD20 monoclonal antibody, ublituximab.
Incyte bullish about virtual launch of rival to CAR-T therapies 06-Aug-2020 By Nick Taylor Incyte talks up ability to successfully launch newly approved blood cancer drug despite disruption caused by COVID-19.
